Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
PurposeThis research investigated the predictive role of metabolic syndrome (MetS) in breast cancer neoadjuvant chemotherapy (BCNACT) response.MethodsOne hundred fifty primary breast cancer (BC) patients who underwent neoadjuvant chemotherapy (NACT) were included retrospectively. MetS, MetS componen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.899335/full |
| _version_ | 1811226816561545216 |
|---|---|
| author | Ying Lu Pinxiu Wang Ning Lan Fei Kong Awaguli Abdumijit Shiyan Tu Yanting Li Wenzhen Yuan |
| author_facet | Ying Lu Pinxiu Wang Ning Lan Fei Kong Awaguli Abdumijit Shiyan Tu Yanting Li Wenzhen Yuan |
| author_sort | Ying Lu |
| collection | DOAJ |
| description | PurposeThis research investigated the predictive role of metabolic syndrome (MetS) in breast cancer neoadjuvant chemotherapy (BCNACT) response.MethodsOne hundred fifty primary breast cancer (BC) patients who underwent neoadjuvant chemotherapy (NACT) were included retrospectively. MetS, MetS components [waist circumference (WC), fasting blood glucose (FBG), blood pressure, triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C)], serum lipid, and other MetS-related laboratory indicators within two weeks before BCNACT were evaluated. Univariate, multivariate, and subgroup analyses were performed to determine the predictors of BCNACT pathologic complete response (pCR), clinical response, and pathologic response. The effectiveness of the model was evaluated via receiver operating characteristic curve (ROC) and calibration curve. External validation was performed through 135 patients.ResultsUnivariate analysis revealed that MetS before BCNACT predicted poor BCNACT response (pCR, P = 0.003; clinical response, P = 0.033; pathologic response, P < 0.001). Multivariate analysis confirmed that MetS before BCNACT predicted lower pCR rate (P = 0.041). Subgroup analysis showed that this relationship was significant in estrogen receptor (ER) (−) (RR = 0.266; 95% CI, 0.074–0.954), human epidermal growth factor 2 (HER2) (−) (RR = 0.833; 95% CI, 0.740–0.939) and TNBC (RR = 0.833; 95% CI, 0.636–0.995). Multivariate analysis of external validation confirmed that pretreatment MetS was associated with a lower pCR rate (P = 0.003), and subgroup analysis also confirmed that this relationship had significant statistical differences in ER (−), HER2 (−), and TNBC subgroups.ConclusionsMetS before BCNACT predicted a lower pCR rate. Intervention on MetS status, especially in ER (−), HER2 (−), and TNBC subgroups, is expected to improve the response rate of BCNACT further. |
| first_indexed | 2024-04-12T09:31:28Z |
| format | Article |
| id | doaj.art-8ff93e49099548799f290d343cf17855 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T09:31:28Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8ff93e49099548799f290d343cf178552022-12-22T03:38:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.899335899335Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast CancerYing Lu0Pinxiu Wang1Ning Lan2Fei Kong3Awaguli Abdumijit4Shiyan Tu5Yanting Li6Wenzhen Yuan7The First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, ChinaPurposeThis research investigated the predictive role of metabolic syndrome (MetS) in breast cancer neoadjuvant chemotherapy (BCNACT) response.MethodsOne hundred fifty primary breast cancer (BC) patients who underwent neoadjuvant chemotherapy (NACT) were included retrospectively. MetS, MetS components [waist circumference (WC), fasting blood glucose (FBG), blood pressure, triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C)], serum lipid, and other MetS-related laboratory indicators within two weeks before BCNACT were evaluated. Univariate, multivariate, and subgroup analyses were performed to determine the predictors of BCNACT pathologic complete response (pCR), clinical response, and pathologic response. The effectiveness of the model was evaluated via receiver operating characteristic curve (ROC) and calibration curve. External validation was performed through 135 patients.ResultsUnivariate analysis revealed that MetS before BCNACT predicted poor BCNACT response (pCR, P = 0.003; clinical response, P = 0.033; pathologic response, P < 0.001). Multivariate analysis confirmed that MetS before BCNACT predicted lower pCR rate (P = 0.041). Subgroup analysis showed that this relationship was significant in estrogen receptor (ER) (−) (RR = 0.266; 95% CI, 0.074–0.954), human epidermal growth factor 2 (HER2) (−) (RR = 0.833; 95% CI, 0.740–0.939) and TNBC (RR = 0.833; 95% CI, 0.636–0.995). Multivariate analysis of external validation confirmed that pretreatment MetS was associated with a lower pCR rate (P = 0.003), and subgroup analysis also confirmed that this relationship had significant statistical differences in ER (−), HER2 (−), and TNBC subgroups.ConclusionsMetS before BCNACT predicted a lower pCR rate. Intervention on MetS status, especially in ER (−), HER2 (−), and TNBC subgroups, is expected to improve the response rate of BCNACT further.https://www.frontiersin.org/articles/10.3389/fonc.2022.899335/fullbreast cancermetabolic syndromeneoadjuvant chemotherapyefficacy predictionMP gradingRECIST criteria |
| spellingShingle | Ying Lu Pinxiu Wang Ning Lan Fei Kong Awaguli Abdumijit Shiyan Tu Yanting Li Wenzhen Yuan Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer Frontiers in Oncology breast cancer metabolic syndrome neoadjuvant chemotherapy efficacy prediction MP grading RECIST criteria |
| title | Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer |
| title_full | Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer |
| title_fullStr | Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer |
| title_full_unstemmed | Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer |
| title_short | Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer |
| title_sort | metabolic syndrome predicts response to neoadjuvant chemotherapy in breast cancer |
| topic | breast cancer metabolic syndrome neoadjuvant chemotherapy efficacy prediction MP grading RECIST criteria |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.899335/full |
| work_keys_str_mv | AT yinglu metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT pinxiuwang metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT ninglan metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT feikong metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT awaguliabdumijit metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT shiyantu metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT yantingli metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer AT wenzhenyuan metabolicsyndromepredictsresponsetoneoadjuvantchemotherapyinbreastcancer |